Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant.

[1]  R. Larson,et al.  Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence , 2009, Leukemia & lymphoma.

[2]  G. Mufti,et al.  Delayed attainment of full donor chimaerism following alemtuzumab‐based reduced‐intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes , 2007, British journal of haematology.

[3]  N. Russell,et al.  The impact of chimerism patterns and predonor leukocyte infusion lymphopenia on survival following T cell-depleted reduced intensity conditioned transplants. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  M. Asaka,et al.  Analysis of donor-type chimerism in lineage-specific cell populations after allogeneic myeloablative and nonmyeloablative stem cell transplantation , 2006, Bone Marrow Transplantation.

[5]  三浦 洋子.  Analysis of donor-type chimerism in lineage-specific cell populations after allogeneic myeloablative and nonmyeloablative stem cell transplantation , 2006 .

[6]  A. Piekarska,et al.  Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease , 2005, Bone Marrow Transplantation.

[7]  R. Storb,et al.  Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning. , 2005, Blood reviews.

[8]  R. Vij,et al.  Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide. , 2005, Blood.

[9]  A. Thiébaut,et al.  Kinetics of Chimerism Conversion to Total Donor Profile: Impact on Transplant Outcome after Reduced Intensity Conditioning Allogeneic Transplantation. , 2004 .

[10]  J. Gribben,et al.  High Levels of Donor Chimerism Early after Non-Myeloablative Transplantation Predictive of Overall and Progression Free Survival but Not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS. , 2004 .

[11]  J. Radich,et al.  Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. , 2004, Blood.

[12]  F. Khan,et al.  Significance of chimerism in hematopoietic stem cell transplantation: new variations on an old theme , 2004, Bone Marrow Transplantation.

[13]  S. Mackinnon,et al.  Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. , 2004, Blood.

[14]  G. Mufti,et al.  BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. , 2004, Blood.

[15]  S. Mackinnon,et al.  Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. , 2003, Blood.

[16]  S. Saidman,et al.  Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  R. López-Pérez,et al.  Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation , 2002, Leukemia.

[18]  C. Craddock,et al.  Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. , 2002, Blood.

[19]  F. Preijers,et al.  Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation , 2002, Leukemia.

[20]  B. Sandmaier,et al.  Non-myeloablative transplantation. , 2002, Hematology. American Society of Hematology. Education Program.

[21]  M. Remberger,et al.  T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation. , 2001, Transplantation.

[22]  G. Morgan,et al.  In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. , 2000, Blood.

[23]  S. Saidman,et al.  Mixed lymphohaemopoietic chimerism and graft-ver suslymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation , 1999, The Lancet.

[24]  L. Barnett,et al.  Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. , 1994, Blood.

[25]  T. Bickle,et al.  New Variations on an Old Theme: Type I Restriction Enzymes and their Recognition Sequences , 1985 .